Medical Affairs as a Strategic Engine: De-Risking Biotech Development and Driving Commercial Success

What if the decisions that determine your drug's commercial success are already being made and medical affairs isn't in the room? In this episode of Medical Affairs Unscripted, Peg Crowley speaks with Nick Sen, SVP and Practice Lead at Lumanity Medical Affairs Consulting, about the evolving role of medical affairs as a strategic driver in biotech and pharmaceutical development. Drawing on experience across academia, commercial strategy, and market access, Nick explains why early medical engagement is no longer optional even for resource-constrained biotech companies. Instead, it is a critical lever for improving clinical, regulatory, and commercial outcomes. They explore three core pillars of medical affairs impact: De-risking clinical development by shaping the Target Product Profile (TPP) with real-world clinical and stakeholder insight Accelerating regulatory approval through early investigator engagement, site selection, and improved trial enrollment Enabling market access and adoption by building an evidence strategy aligned with payer, provider, and patient needs As scientific innovation accelerates across cell therapies, gene therapies, and complex biologics biotech companies must move beyond a narrow focus on regulatory approval and design development programs for real-world adoption and value demonstration. This episode is essential for biotech executives, medical affairs leaders, and cross-functional teams looking to integrate medical strategy earlier in clinical development and strengthen the probability of successful commercialization.